nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

08.12.2017 | Original Article – Clinical Oncology

Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status

verfasst von: Natalie M. Lowe, Jonathan M. Bernstein, Kathleen Mais, Kate Garcez, Lip W. Lee, Andrew Sykes, David J. Thomson, Jarrod J. Homer, Catharine M. West, Nicholas J. Slevin

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most.

Methods

A single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT. TPF involved three cycles of docetaxel (75 mg/m² IV) and cisplatin (75 mg/m² IV) on day 1 plus 5-FU (750 mg/m² IV) on days 2–5. Planned CRT was 66 Gy in 30 fractions of intensity-modulated radiotherapy with concurrent cisplatin (100 mg/m² IV) at the beginning of week 1 and 4 (days 1 and 22). All patients received prophylactic antibiotics and granulocyte colony-stimulating factor.

Results

Median follow-up was 39.5 months. 92.4% of patients completed three cycles of TPF; 95.5% of patients started chemoradiotherapy. Grade 3/4 adverse events were low (febrile neutropenia 3.0%), with no toxicity-related deaths. 3-year overall survival was 67.2%; disease-specific survival was 78.7%; locoregional control was 78.3%. Distant metastases rate was 9.8% (3.0% in those without locoregional recurrence). Good performance status (p = 0.002) and poor tumour differentiation (p = 0.018) were associated with improved overall survival on multivariate analysis.

Conclusion

With prophylactic antibiotics and granulocyte colony-stimulating factor TPF was well tolerated with good survival outcomes. TPF should remain a treatment option for stage IV neck node-positive patients with a good performance status. The use of tumour grade to aid patient selection for TPF warrants investigation.

Nur mit Berechtigung zugänglich

Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98CrossRefPubMed

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer N. Engl J Med 363:24–35. https://doi.org/10.1056/NEJMoa0912217 CrossRef

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940–2950. https://doi.org/10.1200/jco.2013.53.5633 CrossRefPubMedPubMedCentral

Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head neck cancer Lancet 371:1695–1709. https://doi.org/10.1016/s0140-6736(08)60728-x PubMed

Begg AC, Haustermans K, Hart AA, Dische S, Saunders M, Zackrisson B, Gustaffson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot JC, Corvo R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski Z, Dobrowsky W, Struikmans H, Wilson GD et al (1999) The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 50:13–23CrossRefPubMed

Bentzen SM (2003) Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 79:581–585CrossRefPubMed

Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD (2005) Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23:5560–5567. https://doi.org/10.1200/jco.2005.06.411 CrossRefPubMed

Bernstein JM, Kershaw LE, Withey SB, Lowe NM, Homer JJ, Slevin NJ, Bonington SC, Carrington BM, West CM (2015) Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. Oral Oncol 51:508–513. https://doi.org/10.1016/j.oraloncology.2015.01.013 CrossRefPubMed

Blanchard P, Hill C, Guihenneuc-Jouyaux C, Baey C, Bourhis J, Pignon JP (2011) Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 64:985–992. https://doi.org/10.1016/j.jclinepi.2010.10.016 CrossRefPubMed

Bourhis J, Sire C, Graff P, Gregoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Auperin A (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99–02): an open-label phase 3 randomised trial. Lancet Oncol 13:145–153. https://doi.org/10.1016/s1470-2045(11)70346-1 CrossRefPubMed

Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, Mittal BB, Pelzer H, Fung BB, Witt M-E, Wenig B, Portugal L, Weichselbaum RW, Vokes EE (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179–1186. https://doi.org/10.1093/annonc/mdh308 CrossRefPubMed

Budach W, Bolke E, Kammers K, Gerber PA, Orth K, Gripp S, Matuschek C (2016) Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials radiotherapy and oncology. J Eur Soc Ther Radiol Oncol 118:238–243. https://doi.org/10.1016/j.radonc.2015.10.014 CrossRef

Byrd JK, Wilhoit CS, Fordham MT, Reeves TD, McRackan TR, Nguyen SA, Sutkowski N, Gillespie MB (2012) Predicting HPV status in head and neck cancer: the predictive value of sociodemographic and disease characteristics. Arch Otolaryngol Head Neck Surg 138:1155–1159. https://doi.org/10.1001/jamaoto.2013.850 CrossRefPubMed

Chang PH, Yeh KY, Huang JS, Lai CH, Wu TH, Lan YJ, Tsai JC, Chen EY, Yang SW, Wang CH (2013) Pretreatment performance status and nutrition are associated with early mortality of locally advanced head and neck cancer patients undergoing concurrent chemoradiation. Eur Arch Otorhinolaryngol 270:1909–1915. https://doi.org/10.1007/s00405-012-2290-2 CrossRefPubMed

Cohen EE, Karrison T, Kocherginsky M, al e (2012) Docetaxel based chemoradiotherapy plus or minus induction chemotherapy to decrease events in head and neck cancer (DeCIDE). J Clin Oncol 30:suppl 5500

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32:2735–2743. https://doi.org/10.1200/jco.2013.54.6309 CrossRefPubMedPubMedCentral

Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El-Naggar AK, Spitz MR, Schiller JT, Wei Q, Sturgis EM (2003) Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin Cancer Res 9:2620–2626PubMed

Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS (2010) Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2:15. https://doi.org/10.1186/1758-3284-2-15 CrossRefPubMedPubMedCentral

Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M (1997) A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44:123–136CrossRefPubMed

Edge SE, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2009) AJCC Cancer Staging Manual, 7th edn. Spinger, New York

Eriksen JG, Steiniche T, Overgaard J (2005) The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7study. Radiother Oncol 74:93–100CrossRefPubMed

Feyer PC, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K (2011) Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19 Suppl 1:S5–S14. https://doi.org/10.1007/s00520-010-0950-6

Fortin A, Couture C, Doucet R, Albert M, Allard J, Tetu B (2001) Does histologic grade have a role in the management of head and neck cancers? J Clin Oncol 19:4107–4116. https://doi.org/10.1200/jco.2001.19.21.4107 CrossRefPubMed

Garavello W, Ciardo A, Spreafico R, Gaini RM (2006) Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:762–766. https://doi.org/10.1001/archotol.132.7.762 CrossRefPubMed

Ghi MG, Paccagnella A, D Ferrari, P Foa, MC Rocca, E Verri, F Morelli, G Azzarello, C D’Ambrosio, G Cruciani, M Guaraldi, E Massa, C Rossetto, A Bonetti, S Siena, V Minotti, H Koussis, G Pieri, V Baggio, I Floriani, Group ftGIS (2014) Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 32:6004

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codeca C, Nole F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D’Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncology 28:2206–2212. https://doi.org/10.1093/annonc/mdx299

Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720CrossRefPubMed

Guo T, Qualliotine JR, Ha PK, Califano JA, Kim Y, Saunders JR, Blanco RG, D’Souza G, Zhang Z, Chung CH, Kiess A, Gourin CG, Koch W, Richmon JD, Agrawal N, Eisele DW, Fakhry C (2015) Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer 121:1977–1984. https://doi.org/10.1002/cncr.29323 CrossRefPubMedPubMedCentral

Hansen O, Overgaard J, Hansen HS, Overgaard M, Hoyer M, Jorgensen KE, Bastholt L, Berthelsen A (1997) Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol 43:47–51CrossRefPubMed

Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia-Giron C, Irigoyen A, Sastre J, Martinez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernandez JJ (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25:216–225. https://doi.org/10.1093/annonc/mdt461 CrossRefPubMed

Huang SH, Perez-Ordonez B, Liu FF, Waldron J, Ringash J, Irish J, Cummings B, Siu LL, Kim J, Weinreb I, Hope A, Gullane P, Brown D, Shi W, O’Sullivan B (2012) A typical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 82:276–283. https://doi.org/10.1016/j.ijrobp.2010.08.031 CrossRefPubMed

Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V (2010) Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 28:8–14. https://doi.org/10.1200/jco.2009.23.0425 CrossRefPubMed

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159. https://doi.org/10.1016/s1470-2045(10)70279-5 CrossRefPubMedPubMedCentral

Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP (2012) Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol 48:1076–1084. https://doi.org/10.1016/j.oraloncology.2012.06.014 CrossRefPubMed

Miah AB, Schick U, Bhide SA, Guerrero-Urbano MT, Clark CH, Bidmead AM, Bodla S, Del Rosario L, Thway K, Wilson P, Newbold KL, Harrington KJ, Nutting CM (2015) A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes. Br J Cancer 112:32–38. https://doi.org/10.1038/bjc.2014.553 CrossRefPubMed

Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le Q-T (2014) Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. https://doi.org/10.1200/jco.2014.55.3925

O’Sullivan B, Huang SH, Perez-Ordonez B, Massey C, Siu LL, Weinreb I, Hope A, Kim J, Bayley AJ, Cummings B, Ringash J, Dawson LA, Cho BC, Chen E, Irish J, Gilbert RW, Hui A, Liu FF, Zhao H, Waldron JN, Xu W (2012) Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol 103:49–56. https://doi.org/10.1016/j.radonc.2012.02.009 CrossRefPubMed

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed

Petrelli F, Sarti E, Barni S (2014) Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials. Head Neck 36:750–759. https://doi.org/10.1002/hed.23351 CrossRefPubMed

Pignon J-P, Maître A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14. https://doi.org/10.1016/j.radonc.2009.04.014 CrossRefPubMed

Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506. https://doi.org/10.1093/jnci/djp007 CrossRefPubMed

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715. https://doi.org/10.1056/NEJMoa070956 CrossRefPubMed

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III. trial Ann Oncol 22:1071–1077. https://doi.org/10.1093/annonc/mdr006 CrossRefPubMed

Prestwich RJ, Öksüz D, Dyker K, Coyle C, Şen M (2011) Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic stage iv head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 81:e237–e243 https://doi.org/10.1016/j.ijrobp.2011.03.043 CrossRefPubMed

Sinha P, Thorstad WT, Nussenbaum B, Haughey BH, Adkins DR, Kallogjeri D, Lewis Jr (2014) JS Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. Oral oncology 50:45–51. https://doi.org/10.1016/j.oraloncology.2013.10.007 CrossRefPubMed

Slevin NJ, West CM, Wilson GD, Hendry JH (1999) The potential benefit from individualised radiotherapy scheduling for head and neck tumours on the basis of both histological grade and kinetics. Radiother Oncol 51:109–111CrossRefPubMed

Stokes WA, Amini A, Jones BL, McDermott JD, Raben D, Ghosh D, Goddard JA, Bowles DW, Karam SD (2017) Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis. Head Neck 39:1113–1121. https://doi.org/10.1002/hed.24739 CrossRefPubMed

Takacsi-Nagy Z, Hitre E, Remenar E, Oberna F, Polgar C, Major T, Godeny M, Fodor J, Kasler M (2015) Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase. II study Strahlenther Onkol 191:635–641. https://doi.org/10.1007/s00066-015-0829-z CrossRefPubMed

Trosman SJ, Koyfman SA, Ward MC, Al-Khudari S, Nwizu T, Greskovich JF, Lamarre ED, Scharpf J, Khan MJ, Lorenz RR, Adelstein DJ, Burkey BB (2015) Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 141:457–462. https://doi.org/10.1001/jamaoto.2015.136 CrossRefPubMed

Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47CrossRefPubMed

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704. https://doi.org/10.1056/NEJMoa071028 CrossRefPubMed

Vidal L, Ben Aharon I, Limon D, Cohen E, Popovtzer A (2017) Role of induction chemotherapy prior to chemoradiation in head and neck squamous cell cancer—systematic review and meta-analysis. Cancer J 23:79–83. https://doi.org/10.1097/ppo.0000000000000253 CrossRefPubMed

Wilson GD, Saunders MI, Dische S, Daley FM, Buffa FM, Richman PI, Bentzen SM (2006) Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy. Eur J Cancer 42:363–371. https://doi.org/10.1016/j.ejca.2005.10.022 CrossRefPubMed

Won HS, Lee YS, Jeon EK, Hong SH, Kang JH, Kim YS, Yoo le R, Sun DI, Kim MS (2014) Clinical outcome of induction chemotherapy in locally advanced head and neck squamous cell carcinoma. Anticancer Res 34:5709–5714PubMed

Zhang L, Jiang N, Shi Y, Li S, Wang P, Zhao Y (2015) Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. Sci Rep 5:10798. https://doi.org/10.1038/srep10798 CrossRefPubMedPubMedCentral

National Cancer Institute (NCI, NIH, DHHS. May 29, 2009) Common Terminology Criteria for Adverse Events v4.0

Titel: Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status
verfasst von: Natalie M. Lowe
Jonathan M. Bernstein
Kathleen Mais
Kate Garcez
Lip W. Lee
Andrew Sykes
David J. Thomson
Jarrod J. Homer
Catharine M. West
Nicholas J. Slevin
Publikationsdatum: 08.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2553-9

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer

Analysis of TSC1 mutation spectrum in mucosal melanoma

Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer

Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma

Expression profile of microRNA-146a along HPV-induced multistep carcinogenesis: a study in HPV16 transgenic mice

Epigenetic silencing of ADAMTS5 is associated with increased invasiveness and poor survival in patients with colorectal cancer

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie